AMF Tjanstepension 13F: Cuts Danaher (DHR) Stake by $39M
Key Points
- AMF Tjanstepension cut its Danaher Corporation position by 49.3%, ending the period with 179,251 shares valued at about $39.7 million.
- Danaher shares recently traded around $233.97, sitting 8.8% above their 50-day moving average and 3.6% below their 52-week high.
- Major financial firms including Citigroup, Barclays, and JP Morgan recently updated their price targets for the healthcare equipment maker.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
AMF Tjanstepension reduced its investment in Danaher Corporation by 49.3%, cutting 174,440 shares during the period according to a Form 13F filing with the Securities and Exchange Commission on October 22, 2026. The institutional investor disclosed the reduction in a regulatory filing, leaving its total stake at 179,251 shares with a reported value of $39.7 million.
DHR
Danaher Corporation
What Changed in AMF Tjanstepension's Danaher Position
The fund held 353,691 shares of the healthcare and diagnostic products maker prior to the filing. By trimming the position by 174,440 shares down to 179,251 shares, the institution lowered its exposure by nearly half during the quarter.
Other Institutional Activity in Danaher Corporation
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3.56 billion.
Danaher Corporation Stock Up 4.3%
Danaher shares recently traded around $233.97 as of October 22, 2026. The stock sits 8.8% above its 50-day moving average of $215.12 and 16.3% above its 200-day moving average of $201.26. Shares trade 3.6% below their 52-week high of $242.80 and 45.4% above their 52-week low of $160.93, while the consensus target price sits at $247.18.
Recent Earnings
Danaher generated $25.11 billion in trailing twelve month revenue with earnings of $6.04 per share.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share yielding 0.71% with a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Director Alan G. Spoon sold 1,358 shares on May 1, 2026, and Chief Executive Officer Rainer M. Blair disposed of 58,255 shares on August 21, 2026.
Analysts Set New Price Targets
Citigroup maintained a Buy rating and raised its target from $230.00 to $270.00 on October 22, 2026. Barclays kept an Overweight rating and lifted its target from $255.00 to $260.00, while JP Morgan maintained an Overweight rating with a target raised to $270.00. TD Cowen kept a Buy rating and raised its target to $270.00 from $255.00, and Stifel kept a Buy rating while lifting its target to $260.00 from $220.00. The stock carries a consensus Strong Buy rating across 22 analyst opinions.
About Danaher Corporation
Danaher Corporation operates as a global science and technology innovator focused on designing and manufacturing medical, industrial, and research products. The company runs operations across biotechnology, life sciences, and diagnostics segments, providing essential tools and instruments for healthcare providers and scientific laboratories worldwide.
Bottom Line
Institutional portfolio shifts like this one offer a window into how major funds manage their holdings over time. Investors tracking Danaher will monitor upcoming earnings reports and further regulatory filings to gauge ongoing institutional demand for the stock.
Related Filing Alerts
Source: AMF Tjanstepension's 13F filing on $DHR (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts